Adaptive Biotechnologies (ADPT) Cash from Financing Activities (2018 - 2026)

Adaptive Biotechnologies has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $7.5 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $7.5 million, up 37.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.5 million (up 474.58% YoY), and the FY2025 annual result was $30.4 million, up 12515.35% from the prior year.
• Cash from Financing Activities came in at $7.5 million for Q1 2026 at Adaptive Biotechnologies, down from $21.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $125.5 million in Q3 2022 to a low of $6000.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $1.5 million (2023), against an average of $10.2 million.
• Across the five-year window, Cash from Financing Activities plunged 99.99% in 2023 and jumped 16953.54% in 2025, its largest moves.
• Adaptive Biotechnologies' Cash from Financing Activities stood at $6000.0 in 2022, then surged by 1350.0% to $87000.0 in 2023, then soared by 45.98% to $127000.0 in 2024, then surged by 16953.54% to $21.7 million in 2025, then sank by 65.37% to $7.5 million in 2026.
• The last three Cash from Financing Activities figures came in at $7.5 million (Q1 2026), $21.7 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.